Kiniksa Pharmaceuticals International, plc
KNSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001730430
In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders filed 0 open-market purchases and 2 sales; 267 institutions reported holding it in 13F filings for Q2 2026, worth $2.99B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Kiniksa Pharmaceuticals International, plc changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 133 | 1 | 176 | +44 |
| Shares | 35.3M | 4.59M | 39.7M | +8.92M (+29.0%) |
| Value | $659.4M | $85.7M | $991.2M | +$417.5M (+72.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (60)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (16)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| SG Americas Securities, LLC | 69,226 | $1.29M |
| Rafferty Asset Management, LLC | 60,614 | $1.13M |
| Y-Intercept (Hong Kong) Ltd | 29,093 | $543.2K |
| Janney Montgomery Scott LLC | 28,231 | $525.0K |
| Squarepoint Ops LLC | 24,845 | $463.9K |
| Robeco Institutional Asset Management B.V. | 15,982 | $298.4K |
| QRG Capital Management, Inc. | 14,033 | $261.9K |
| Sherbrooke Park Advisers LLC | 11,733 | $219.1K |
| Profund Advisors LLC | 11,504 | $214.8K |
| Aquatic Capital Management LLC | 11,000 | $205.4K |
| EntryPoint Capital, LLC | 10,076 | $188.1K |
| Ashton Thomas Private Wealth, LLC | 5,361 | $100.1K |
| Caption Management, LLC | 4,065 | $75.9K |
| State of Wyoming | 3,893 | $72.7K |
| Adirondack Trust Co | 875 | $16.3K |
| Pacer Advisors, Inc. | 345 | $6.44K |
Not filed for Q3 2024 yet (1)
Institutions that held Kiniksa Pharmaceuticals International, plc at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 4,591,136 | $85.7M |